CR20140397A - Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks - Google Patents
Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ksInfo
- Publication number
- CR20140397A CR20140397A CR20140397A CR20140397A CR20140397A CR 20140397 A CR20140397 A CR 20140397A CR 20140397 A CR20140397 A CR 20140397A CR 20140397 A CR20140397 A CR 20140397A CR 20140397 A CR20140397 A CR 20140397A
- Authority
- CR
- Costa Rica
- Prior art keywords
- oxazolidin
- inhibitors
- pi3ks
- same
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se relaciona con compuestos de pirimidina oxazolidin- 2-ona sustituidos que actúan como inhibidores de la PI3K (fosfatidilinositol- 5 3- quinasa), así como también composiciones farmacéuticas de los mismos, métodos para sufabricación y usos para el tratamiento de condiciones, enfermedades y trastornos dependientes de PI3K. WO 2013/124826 A1.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261602954P | 2012-02-24 | 2012-02-24 | |
US201261736707P | 2012-12-13 | 2012-12-13 | |
PCT/IB2013/051443 WO2013124826A1 (en) | 2012-02-24 | 2013-02-22 | Oxazolidin- 2 -one compounds and uses thereof as pi3ks inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20140397A true CR20140397A (es) | 2014-10-16 |
Family
ID=48142031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20140397A CR20140397A (es) | 2012-02-24 | 2014-08-22 | Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks |
Country Status (31)
Country | Link |
---|---|
US (2) | US8865894B2 (es) |
EP (1) | EP2817307B1 (es) |
JP (1) | JP6154404B2 (es) |
KR (1) | KR101640698B1 (es) |
CN (1) | CN104144926B (es) |
AP (1) | AP2014007835A0 (es) |
AR (1) | AR090121A1 (es) |
AU (1) | AU2013223713C1 (es) |
BR (1) | BR112014020672B1 (es) |
CA (1) | CA2865372A1 (es) |
CO (1) | CO7051028A2 (es) |
CR (1) | CR20140397A (es) |
DO (1) | DOP2014000194A (es) |
EA (1) | EA026031B1 (es) |
ES (1) | ES2598118T3 (es) |
GE (1) | GEP20156389B (es) |
GT (1) | GT201400178A (es) |
HK (1) | HK1199643A1 (es) |
IL (1) | IL233936A (es) |
MX (1) | MX353341B (es) |
NI (1) | NI201400089A (es) |
NZ (1) | NZ629198A (es) |
PE (1) | PE20142456A1 (es) |
PH (1) | PH12014501900A1 (es) |
PL (1) | PL2817307T3 (es) |
PT (1) | PT2817307T (es) |
SG (1) | SG11201404794XA (es) |
TW (1) | TW201339155A (es) |
UY (1) | UY34632A (es) |
WO (1) | WO2013124826A1 (es) |
ZA (1) | ZA201405446B (es) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2849995A1 (en) | 2011-09-27 | 2013-04-04 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
KR20150131224A (ko) | 2013-03-14 | 2015-11-24 | 노파르티스 아게 | 돌연변이 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
US20150259420A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
WO2015148379A1 (en) | 2014-03-24 | 2015-10-01 | Novartis Ag | Monobactam organic compounds for the treatment of bacterial infections |
TW201609108A (zh) | 2014-07-25 | 2016-03-16 | 諾華公司 | 醫藥劑型 |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
CR20170143A (es) | 2014-10-14 | 2017-06-19 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas |
ES2749679T3 (es) | 2014-10-22 | 2020-03-23 | Bristol Myers Squibb Co | Compuestos de pirrolotriazina amina sustituidos como inhibidores de PI3k |
WO2016064957A1 (en) | 2014-10-22 | 2016-04-28 | Bristol-Myers Squibb Company | Bicyclic heteroaryl amine compounds as pi3k inhibitors |
WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
SG11201706756VA (en) | 2015-03-10 | 2017-09-28 | Aduro Biotech Inc | Compositions and methods for activating "stimulator of interferon gene" -dependent signalling |
JP6522807B2 (ja) * | 2015-07-02 | 2019-05-29 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ベンゾオキサゼピンオキサゾリジノン化合物及び使用方法 |
US9650393B2 (en) | 2015-07-02 | 2017-05-16 | Genentech, Inc. | Benzoxazepin oxazolidinone compounds and methods of use |
DK3317301T3 (da) | 2015-07-29 | 2021-06-28 | Immutep Sas | Kombinationsterapier omfattende antistofmolekyler mod lag-3 |
EP4378957A2 (en) | 2015-07-29 | 2024-06-05 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
WO2017019897A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
EP3370768B9 (en) | 2015-11-03 | 2022-03-16 | Janssen Biotech, Inc. | Antibodies specifically binding pd-1 and their uses |
CN108495651A (zh) | 2015-12-17 | 2018-09-04 | 诺华股份有限公司 | 抗pd-1的抗体分子及其用途 |
EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
AU2017355385A1 (en) * | 2016-11-02 | 2019-05-30 | Curis, Inc. | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
CA3066774A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES |
US11919902B2 (en) | 2017-12-22 | 2024-03-05 | Hibercell, Inc. | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors |
AR126019A1 (es) | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
CN109134558A (zh) * | 2018-09-21 | 2019-01-04 | 常州方圆制药有限公司 | 一种提高1-N-乙基庆大霉素Cla收率的合成方法 |
CN109970764B (zh) * | 2019-03-26 | 2021-11-09 | 上海吉奉生物科技有限公司 | 一种(S)-1,1,5,5-四甲基二氢恶唑并[3,4-c]恶唑-3-酮的合成方法 |
WO2021053559A1 (en) | 2019-09-18 | 2021-03-25 | Novartis Ag | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
Family Cites Families (124)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB581334A (en) | 1943-09-29 | 1946-10-09 | Francis Henry Swinden Curd | New pyrimidine compounds |
JPS4921148Y1 (es) | 1970-02-07 | 1974-06-06 | ||
JPS4921149Y1 (es) | 1970-06-27 | 1974-06-06 | ||
JPS4921149B1 (es) | 1970-12-28 | 1974-05-30 | ||
JPS4921148B1 (es) | 1970-12-28 | 1974-05-30 | ||
DE2341925A1 (de) | 1973-08-20 | 1975-03-06 | Thomae Gmbh Dr K | Neue pyrimidinderivate und verfahren zu ihrer herstellung |
AT340933B (de) | 1973-08-20 | 1978-01-10 | Thomae Gmbh Dr K | Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze |
US4261989A (en) | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
US4994386A (en) | 1987-07-13 | 1991-02-19 | Pharmacia Diagnostics, Inc. | Production of HBLV virus in the HSB-2 cell line |
US4929726A (en) | 1988-02-09 | 1990-05-29 | Georgia State University Foundation, Inc. | Novel diazines and their method of preparation |
EP0330263A1 (en) | 1988-02-25 | 1989-08-30 | Merck & Co. Inc. | Piperazinylalkylpyrimidines as hypoglycemic agents |
GB9012311D0 (en) | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
WO1992000970A1 (fr) | 1990-07-03 | 1992-01-23 | Mitsui Petrochemical Industries, Limited | Compose de pyrimidine et sel pharmaceutiquement acceptable de ce compose |
EP0767170B1 (en) | 1995-04-13 | 2002-10-23 | Taiho Pharmaceutical Co., Ltd. | Novel 4,6-diarylpyrimidine derivatives and salts thereof |
JP3734907B2 (ja) | 1996-12-19 | 2006-01-11 | 富士写真フイルム株式会社 | 現像処理方法 |
AU727013B2 (en) | 1997-07-24 | 2000-11-30 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent comprising the same as effective component |
JPH11158073A (ja) | 1997-09-26 | 1999-06-15 | Takeda Chem Ind Ltd | アデノシンa3拮抗剤 |
US6440965B1 (en) | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
US6150362A (en) | 1997-12-12 | 2000-11-21 | Henkin; Jack | Triazine angiogenesis inhibitors |
ATE236136T1 (de) | 1998-01-16 | 2003-04-15 | Hoffmann La Roche | Benzosulfonderivate |
US7045519B2 (en) | 1998-06-19 | 2006-05-16 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
JP4533534B2 (ja) | 1998-06-19 | 2010-09-01 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | グリコーゲンシンターゼキナーゼ3のインヒビター |
US6495558B1 (en) | 1999-01-22 | 2002-12-17 | Amgen Inc. | Kinase inhibitors |
CA2359680A1 (en) | 1999-01-22 | 2000-07-27 | David M. Armistead | Kinase inhibitors |
EP1206265B1 (en) | 1999-06-30 | 2003-11-12 | Merck & Co., Inc. | Src kinase inhibitor compounds |
WO2001000207A1 (en) | 1999-06-30 | 2001-01-04 | Merck & Co., Inc. | Src kinase inhibitor compounds |
CA2376951A1 (en) | 1999-06-30 | 2001-01-04 | Peter J. Sinclair | Src kinase inhibitor compounds |
ATE250053T1 (de) | 1999-07-15 | 2003-10-15 | Pharmacopeia Inc | Bradikinin b1 rezeptor antagonisten |
JP2001089452A (ja) | 1999-09-22 | 2001-04-03 | Sankyo Co Ltd | ピリミジン誘導体 |
US20030004174A9 (en) | 2000-02-17 | 2003-01-02 | Armistead David M. | Kinase inhibitors |
IL151946A0 (en) | 2000-03-29 | 2003-04-10 | Cyclacel Ltd | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders |
CN1186324C (zh) | 2000-04-27 | 2005-01-26 | 山之内制药株式会社 | 稠合杂芳基衍生物 |
KR100711042B1 (ko) | 2000-04-28 | 2007-04-24 | 다나베 세이야꾸 가부시키가이샤 | 환상 화합물 |
EP1296977A1 (en) | 2000-06-23 | 2003-04-02 | Bristol-Myers Squibb Pharma Company | Heteroaryl-phenyl substituted factor xa inhibitors |
EP1317433A2 (en) | 2000-09-06 | 2003-06-11 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
AU2001291013A1 (en) | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
SE0004053D0 (sv) | 2000-11-06 | 2000-11-06 | Astrazeneca Ab | N-type calcium channel antagonists for the treatment of pain |
HUP0400908A3 (en) | 2000-12-21 | 2010-03-29 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors, their use and pharmaceutical compositions containing them |
WO2002062766A2 (en) | 2001-02-07 | 2002-08-15 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
AU2002258400A1 (en) | 2001-02-16 | 2002-08-28 | Tularik Inc. | Methods of using pyrimidine-based antiviral agents |
WO2002096876A1 (en) | 2001-05-25 | 2002-12-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Carbamate and oxamide compounds as inhibitors of cytokine production |
EP1397142A4 (en) | 2001-06-19 | 2004-11-03 | Bristol Myers Squibb Co | PYRIMIDINE PHOSPHODIESTERASE (PDE) INHIBITORS 7 |
US6603000B2 (en) | 2001-07-11 | 2003-08-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Synthesis for heteroarylamine compounds |
WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
EP1485380B1 (en) | 2002-03-15 | 2010-05-19 | Vertex Pharmaceuticals Incorporated | Azolylaminoazines as inhibitors of protein kinases |
ATE466580T1 (de) | 2002-03-15 | 2010-05-15 | Vertex Pharma | Azolylaminoazine als proteinkinasehemmer |
DE60314603T2 (de) | 2002-03-15 | 2008-02-28 | Vertex Pharmaceuticals Inc., Cambridge | Zusammensetzungen brauchbar als protein-kinase-inhibitoren |
US7179826B2 (en) | 2002-03-15 | 2007-02-20 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
AU2003245669A1 (en) | 2002-06-21 | 2004-01-06 | Cellular Genomics, Inc. | Certain aromatic monocycles as kinase modulators |
DE10228103A1 (de) | 2002-06-24 | 2004-01-15 | Bayer Cropscience Ag | Fungizide Wirkstoffkombinationen |
AU2003275242B2 (en) | 2002-09-27 | 2010-03-04 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
JP2006515274A (ja) | 2002-10-08 | 2006-05-25 | マサチューセッツ・インスティテュート・オブ・テクノロジー | コレステロール輸送の調節のための化合物 |
US7223870B2 (en) | 2002-11-01 | 2007-05-29 | Pfizer Inc. | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction |
CA2507100C (en) | 2002-11-21 | 2012-10-09 | Chiron Corporation | 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer |
CA2519677A1 (en) | 2003-03-24 | 2004-10-07 | Merck & Co., Inc. | Biaryl substituted 6-membered heterocycles as sodium channel blockers |
US20050014753A1 (en) | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
JP4895806B2 (ja) | 2003-04-09 | 2012-03-14 | エクセリクシス, インク. | Tie−2モジュレータと使用方法 |
WO2005002514A2 (en) | 2003-06-13 | 2005-01-13 | Echelon Biosciences Incorporated | Compounds having inhibitibe activity of phosphatidylinositol 3-kinase and methods of use thereof |
US20060229308A1 (en) | 2003-07-15 | 2006-10-12 | Neurogen Corporation | Substituted pyrirmidin-4-ylamine analogues as vanilloid receptor ligands |
JP2007534624A (ja) | 2003-07-16 | 2007-11-29 | ニューロジェン・コーポレーション | ビアリールピペラジニル−ピリジン類縁体 |
US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
PE20050952A1 (es) * | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
WO2005099711A1 (en) | 2004-04-13 | 2005-10-27 | Icagen, Inc. | Polycyclic pyrimidines as potassium ion channel modulators |
GB0415365D0 (en) * | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
GB0415364D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
MY145822A (en) | 2004-08-13 | 2012-04-30 | Neurogen Corp | Substituted biaryl piperazinyl-pyridine analogues |
JP2008521900A (ja) | 2004-11-30 | 2008-06-26 | アムジエン・インコーポレーテツド | キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用 |
JP2008523156A (ja) | 2004-12-13 | 2008-07-03 | ニューロジェン・コーポレーション | 置換ビアリール類縁体 |
CA2590299A1 (en) | 2004-12-13 | 2006-06-22 | Neurogen Corporation | Piperazinyl-pyridine analogues |
CN101184734B (zh) | 2004-12-28 | 2013-05-29 | 金克斯医药品有限公司 | 治疗细胞增殖紊乱的化合物和方法 |
US20080124384A1 (en) | 2005-01-19 | 2008-05-29 | Blum Charles A | Heteroaryl Substituted Piperazinyl-Pyridine Analogues |
MX2007010404A (es) | 2005-02-25 | 2008-01-11 | Kudos Pharm Ltd | Hidrazinometilo, hidrazonometilo y compuestos heterociclicos de 5 miembros que actuan como inhibidores de mtor y su uso como agentes anti-cancer. |
AU2006236387A1 (en) | 2005-04-18 | 2006-10-26 | Neurogen Corporation | Subtituted heteroaryl CB1 antagonists |
CA2613122C (en) | 2005-06-29 | 2013-01-22 | Compumedics Limited | Sensor assembly with conductive bridge |
GB2431156A (en) | 2005-10-11 | 2007-04-18 | Piramed Ltd | 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase |
JP2009523161A (ja) | 2006-01-11 | 2009-06-18 | アストラゼネカ アクチボラグ | モルホリノピリミジン誘導体と療法におけるその使用 |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
EP2012794B1 (en) * | 2006-04-13 | 2014-09-17 | The Trustees of Columbia University in the City of New York | Compositions and intraluminal devices for inhibiting vascular stenosis |
TW200833342A (en) | 2006-12-28 | 2008-08-16 | Basf Ag | 2-substituted pyrimidines I in therapy |
WO2008098058A1 (en) | 2007-02-06 | 2008-08-14 | Novartis Ag | Pi 3-kinase inhibitors and methods of their use |
US7957951B2 (en) | 2007-03-16 | 2011-06-07 | Robert Bosch Gmbh | Address translation system for use in a simulation environment |
BRPI0814818A2 (pt) | 2007-07-09 | 2019-09-10 | Astrazeneca Ab | composto, uso de um composto, métodos para produzir um efeito anti-proliferativo e um efeito inibitório de mtor quinase em uma animal de sangue quente, método para tratar doenças, e, composição farmacêutica |
WO2009066084A1 (en) * | 2007-11-21 | 2009-05-28 | F. Hoffmann-La Roche Ag | 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors |
AU2009221164B2 (en) | 2008-03-05 | 2012-07-26 | Novartis Ag | Use of pyrimidine derivatives for the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members |
MX338088B (es) | 2008-03-26 | 2016-04-01 | Novartis Ag | Imidazoquinolinas y derivados de pirimidina como moduladores potentes de los procesos angiogenicos impulsados por el factor de crecimiento endotelial vascular (vegf). |
JP2011515462A (ja) | 2008-03-27 | 2011-05-19 | アウククランド ウニセルビセス リミテッド | 置換されたピリミジン、及びトリアジン、並びに癌療法におけるこれらの使用 |
WO2009125870A1 (en) | 2008-04-09 | 2009-10-15 | Mitsubishi Tanabe Pharma Corporation | Pyrimidine, pyridine and triazine derivatives as maxi-k channel openers. |
GB0815369D0 (en) | 2008-08-22 | 2008-10-01 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
JP2012506898A (ja) | 2008-10-31 | 2012-03-22 | ノバルティス アーゲー | ホスファチジルイノシトール−3−キナーゼ(PI3K)阻害剤とmTOR阻害剤との併用剤 |
GB2465405A (en) | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
US8513242B2 (en) | 2008-12-12 | 2013-08-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
MY155374A (en) | 2009-02-06 | 2015-10-15 | Nippon Shinyaku Co Ltd | Aminopyrazine derivative and medicine |
JP5747440B2 (ja) | 2009-02-06 | 2015-07-15 | 住友化学株式会社 | ヒドラジド化合物及びその有害生物防除用途 |
EP2406389B1 (en) | 2009-03-13 | 2019-05-08 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
WO2010120994A2 (en) | 2009-04-17 | 2010-10-21 | Wyeth Llc | Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis |
PT2432767E (pt) | 2009-05-19 | 2013-07-25 | Dow Agrosciences Llc | Compostos e métodos para controlo de fungos |
AR080945A1 (es) | 2009-07-07 | 2012-05-23 | Pathway Therapeutics Inc | Pirimidinil y 1,3,5-triazinil benzimidazoles y su uso en la terapia contra el cancer |
AR077695A1 (es) | 2009-08-04 | 2011-09-14 | Schering Corp | Derivados de pirimidina como inhibidores del factor ixa |
AR077999A1 (es) | 2009-09-02 | 2011-10-05 | Vifor Int Ag | Antagonistas de pirimidin y triazin-hepcidina |
KR20120063515A (ko) | 2009-09-09 | 2012-06-15 | 아빌라 테라퓨틱스, 인크. | Pi3 키나제 억제제 및 이들의 용도 |
WO2011072174A1 (en) | 2009-12-09 | 2011-06-16 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation |
GB201004200D0 (en) | 2010-03-15 | 2010-04-28 | Univ Basel | Spirocyclic compounds and their use as therapeutic agents and diagnostic probes |
AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
EP2560488B1 (en) | 2010-04-23 | 2015-10-28 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
WO2011143160A2 (en) | 2010-05-10 | 2011-11-17 | The Johns Hopkins University | Metabolic inhibitor against tumors having an idh mutation |
WO2012009678A1 (en) | 2010-07-16 | 2012-01-19 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their method of use |
DK3040333T3 (da) | 2010-10-01 | 2019-01-02 | Novartis Ag | Krystallinske former af 5-(2,6-di-4-morpholinyl-4-pyridmidinyl)-4-trifluormethylpyridin-2-amin, en pik3-hæmmer |
LT2629776T (lt) | 2010-10-18 | 2017-11-10 | Cerenis Therapeutics Holding Sa | Junginiai, kompozicijos ir būdai, tinkami cholesterolio mobilizavimui |
GB201106829D0 (en) | 2011-04-21 | 2011-06-01 | Proximagen Ltd | Heterocyclic compounds |
EP2673268A1 (en) | 2011-02-11 | 2013-12-18 | Dana-Farber Cancer Institute, Inc. | Method of inhibiting hamartoma tumor cells |
CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
BR112014004577A2 (pt) | 2011-09-01 | 2017-04-04 | Novartis Ag | inibidor pi3k para uso no tratamento de câncer ósseo ou para prevenção por metástase de células cancerosas primárias para os ossos |
CA2849995A1 (en) | 2011-09-27 | 2013-04-04 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
WO2013052395A1 (en) | 2011-10-06 | 2013-04-11 | Merck Sharp & Dohme Corp. | 1,3-substituted azetidine pde10 inhibitors |
UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
CA2872526A1 (en) | 2012-05-16 | 2013-11-21 | Novartis Ag | Dosage regimen for a pi-3 kinase inhibitor |
EP2858631A1 (en) | 2012-06-06 | 2015-04-15 | Novartis AG | Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease |
US20150216870A1 (en) | 2012-08-16 | 2015-08-06 | Novartis Ag | Combination of PI3K Inhibitor and C-Met Inhibitor |
AU2013336807B2 (en) | 2012-10-23 | 2016-10-27 | Novartis Ag | Improved process for manufacturing 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine |
US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
KR20150131224A (ko) | 2013-03-14 | 2015-11-24 | 노파르티스 아게 | 돌연변이 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온 |
CN103483345B (zh) | 2013-09-25 | 2016-07-06 | 中山大学 | Pi3k激酶抑制剂、包含其的药物组合物及其应用 |
CN103694218B (zh) | 2013-12-05 | 2016-04-27 | 中山大学 | 嘧啶化合物、pi3k抑制剂、包含pi3k抑制剂的药物组合物及应用 |
-
2013
- 2013-02-21 UY UY0001034632A patent/UY34632A/es not_active Application Discontinuation
- 2013-02-22 SG SG11201404794XA patent/SG11201404794XA/en unknown
- 2013-02-22 CN CN201380010698.9A patent/CN104144926B/zh active Active
- 2013-02-22 TW TW102106331A patent/TW201339155A/zh unknown
- 2013-02-22 EP EP13717317.5A patent/EP2817307B1/en active Active
- 2013-02-22 ES ES13717317.5T patent/ES2598118T3/es active Active
- 2013-02-22 AR ARP130100536A patent/AR090121A1/es unknown
- 2013-02-22 KR KR1020147023243A patent/KR101640698B1/ko active IP Right Grant
- 2013-02-22 EA EA201491579A patent/EA026031B1/ru not_active IP Right Cessation
- 2013-02-22 MX MX2014010141A patent/MX353341B/es active IP Right Grant
- 2013-02-22 PL PL13717317T patent/PL2817307T3/pl unknown
- 2013-02-22 AP AP2014007835A patent/AP2014007835A0/xx unknown
- 2013-02-22 NZ NZ629198A patent/NZ629198A/en not_active IP Right Cessation
- 2013-02-22 AU AU2013223713A patent/AU2013223713C1/en active Active
- 2013-02-22 CA CA2865372A patent/CA2865372A1/en not_active Abandoned
- 2013-02-22 PE PE2014001291A patent/PE20142456A1/es not_active Application Discontinuation
- 2013-02-22 GE GEAP201313557A patent/GEP20156389B/en unknown
- 2013-02-22 WO PCT/IB2013/051443 patent/WO2013124826A1/en active Application Filing
- 2013-02-22 PT PT137173175T patent/PT2817307T/pt unknown
- 2013-02-22 JP JP2014558256A patent/JP6154404B2/ja active Active
- 2013-02-22 US US13/773,947 patent/US8865894B2/en active Active
- 2013-02-22 BR BR112014020672-4A patent/BR112014020672B1/pt active IP Right Grant
-
2014
- 2014-07-23 ZA ZA2014/05446A patent/ZA201405446B/en unknown
- 2014-08-04 IL IL233936A patent/IL233936A/en not_active IP Right Cessation
- 2014-08-12 NI NI201400089A patent/NI201400089A/es unknown
- 2014-08-15 CO CO14179492A patent/CO7051028A2/es unknown
- 2014-08-22 CR CR20140397A patent/CR20140397A/es unknown
- 2014-08-22 GT GT201400178A patent/GT201400178A/es unknown
- 2014-08-22 PH PH12014501900A patent/PH12014501900A1/en unknown
- 2014-08-22 DO DO2014000194A patent/DOP2014000194A/es unknown
- 2014-09-05 US US14/478,523 patent/US9458177B2/en active Active
-
2015
- 2015-01-02 HK HK15100012.7A patent/HK1199643A1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20140397A (es) | Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks | |
CR20150248A (es) | Derivados de oxazolidin-2-ona-pirimidina | |
CL2017002650A1 (es) | Compuestos novedosos | |
SV2015005066A (es) | Compuestos de biaril-amida como inhibidores de cinasa | |
CR20150255A (es) | Derivados triciclicos fusionados de tiofeno como inhibidores de jak | |
CR20150425A (es) | Compuestos azabencimidazol como inhibidores de las isozimas pde4, para el tratamiento del sistema nervioso central y otros desórdenes | |
TR201901886T4 (tr) | DNA-PK inhibitörleri. | |
PH12016501160A1 (en) | Isochromene derivatives as phosphoinositide 3-kinases inhibitors | |
DOP2012000257A (es) | Derivados del acido 1-amino-2-ciclopropiletilboronico | |
CL2015000956A1 (es) | Compuestos derivados de pirrolotriazinona como inhibidores de pi3k; composicion farmaceutica que los comprende; combinacion farmaceutica; uso para tratar enfermedades respiratorias, autoinmunes, trastornos neurologicos, cardiovasculares, metabolicos, entre otros. | |
DOP2014000253A (es) | Inhibidores del nampt | |
CR20130464A (es) | Inhibidores sustituidos de acetil-coa carboxilasa | |
GT201400242A (es) | "nuevos compuestos de pirazol" | |
CL2017000827A1 (es) | Inhibidores de aldosterona sintasa | |
CU20140102A7 (es) | Compuestos de oxazolidin-2- ona y usos de los mismos como inhibidores de la p13ks | |
AR122753A2 (es) | Inhibidores selectivos de proteínas cinasas delta pi3k, composiciones farmacéuticas, usos, y métodos de tratamiento y/o prevención de las enfermedades o trastornos mediados por cinasas | |
ECSP15021681A (es) | Derivados tricíclicos fusionados de tiofeno como inhibidores de jak |